JP2023521150A - コロナウイルス感染の阻害および処置に使用するための銀ナノ粒子 - Google Patents

コロナウイルス感染の阻害および処置に使用するための銀ナノ粒子 Download PDF

Info

Publication number
JP2023521150A
JP2023521150A JP2022561651A JP2022561651A JP2023521150A JP 2023521150 A JP2023521150 A JP 2023521150A JP 2022561651 A JP2022561651 A JP 2022561651A JP 2022561651 A JP2022561651 A JP 2022561651A JP 2023521150 A JP2023521150 A JP 2023521150A
Authority
JP
Japan
Prior art keywords
silver nanoparticles
suspension
use according
infection
preferred embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022561651A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021207178A5 (https=
JP2023521150A5 (https=
Inventor
アガーワル，アンキット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2023521150A publication Critical patent/JP2023521150A/ja
Publication of JPWO2021207178A5 publication Critical patent/JPWO2021207178A5/ja
Publication of JP2023521150A5 publication Critical patent/JP2023521150A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022561651A 2020-04-06 2021-04-06 コロナウイルス感染の阻害および処置に使用するための銀ナノ粒子 Pending JP2023521150A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063005727P 2020-04-06 2020-04-06
US63/005,727 2020-04-06
PCT/US2021/025942 WO2021207178A1 (en) 2020-04-06 2021-04-06 Silver nanoparticles for use in inhibiting and treating coronavirus infection

Publications (3)

Publication Number Publication Date
JP2023521150A true JP2023521150A (ja) 2023-05-23
JPWO2021207178A5 JPWO2021207178A5 (https=) 2024-04-17
JP2023521150A5 JP2023521150A5 (https=) 2024-04-17

Family

ID=78023543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561651A Pending JP2023521150A (ja) 2020-04-06 2021-04-06 コロナウイルス感染の阻害および処置に使用するための銀ナノ粒子

Country Status (5)

Country Link
US (1) US20230158067A1 (https=)
EP (1) EP4132467A4 (https=)
JP (1) JP2023521150A (https=)
CN (1) CN115551482A (https=)
WO (1) WO2021207178A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250338852A1 (en) * 2022-05-30 2025-11-06 Shin-Etsu Chemical Co., Ltd. Antiviral composition and member having same on surface

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523063A (ja) * 2004-12-06 2008-07-03 ノヴァセントリックス コープ 金属ナノ材料組成の抗ウィルス使用法
CN102579490A (zh) * 2012-02-22 2012-07-18 大连大学 一种纳米银抗病毒溶液及其制作方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135195B2 (en) * 1999-06-01 2006-11-14 American Silver, Llc Treatment of humans with colloidal silver composition
AU2003304507A1 (en) * 2003-10-16 2005-05-05 Toagosei Co., Ltd. Anti-coronavirus agent
KR20050077887A (ko) * 2004-01-28 2005-08-04 (주)지피엔이 코로나 바이러스 및 인플루엔자 바이러스 등에 억제능이있는 나노무기항균제
US20130315972A1 (en) * 2012-05-24 2013-11-28 Agienic, Inc. Compositions and methods for antimicrobial metal nanoparticles
WO2012174466A2 (en) * 2011-06-17 2012-12-20 Annuary Healthcare, Inc. Nanoscale particle formulations and methods
CN102861102A (zh) * 2012-09-21 2013-01-09 华绣科技有限公司 一种纳米银抑菌喷剂
US20160081346A1 (en) * 2014-09-23 2016-03-24 Attostat, Inc. Antimicrobial compositions and methods
WO2016161348A1 (en) * 2015-04-01 2016-10-06 Attostat, Inc. Nanoparticle compositions and methods for treating or preventing tissue infections and diseases
CN105412379A (zh) * 2015-12-09 2016-03-23 刘传新 一种吸入式治疗肺结核制剂及其制备方法
SI25804A (sl) * 2020-03-19 2020-09-30 Danijela Marković Koloidno srebro za uporabo in postopek njegove priprave

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523063A (ja) * 2004-12-06 2008-07-03 ノヴァセントリックス コープ 金属ナノ材料組成の抗ウィルス使用法
CN102579490A (zh) * 2012-02-22 2012-07-18 大连大学 一种纳米银抗病毒溶液及其制作方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 533, JPN6025012302, September 2020 (2020-09-01), pages 195 - 200, ISSN: 0005563329 *
J. NANOPART. RES., vol. 19, JPN6025012300, 2017, ISSN: 0005563327 *
MOLECULES, vol. 16, JPN6025012299, 2011, pages 8894 - 8918, ISSN: 0005563326 *
SCIENCEOPEN, JPN6025012301, 28 March 2020 (2020-03-28), ISSN: 0005563328 *
WIRES NANOMED. NANOBIOTECHNOL., JPN6025012303, February 2021 (2021-02-01), ISSN: 0005563330 *

Also Published As

Publication number Publication date
CN115551482A (zh) 2022-12-30
US20230158067A1 (en) 2023-05-25
WO2021207178A1 (en) 2021-10-14
EP4132467A1 (en) 2023-02-15
EP4132467A4 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
PL199782B1 (pl) Środek do nosa do zapobiegania i leczenia wirusowego przeziębienia i grypy
CN116075306B (zh) 用于治疗冠状病毒感染的化合物
CA2714286C (en) The use of an acetylsalicylic acid salt for treating viral infections
JP2774379B2 (ja) 医薬エアロゾール組成物ならびにそれらのウイルス疾患の治療および予防用途
US8709496B2 (en) Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract
ES2342935T3 (es) Composiciones para prevencion y tratamiento de sintomas de tipo resfriado y gripe que comprenden polimeros mucoadhesivos seleccionados.
WO2022055958A1 (en) Niclosamide particles and uses thereof
CN115427076A (zh) 用于治疗冠状病毒感染的人去泛素化酶抑制剂
US20240075029A1 (en) Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection
JP2023521150A (ja) コロナウイルス感染の阻害および処置に使用するための銀ナノ粒子
CN103153315A (zh) 用吸入地纽福索治疗囊性纤维化的方法
US20250352558A1 (en) Water-soluble cannabidiol compositions and method for preparation of water-soluble cannabidiol
HK40086332A (zh) 用於抑制和治疗冠状病毒感染的银纳米颗粒
WO2023023647A2 (en) Compositions and methods for bimodal anti-viral combination therapy
WO2022046668A1 (en) Compositions and methods for reducing the transmissivity of illnesses
TW201016215A (en) Compositions and uses of antiviral active pharmaceutical agents
WO2021211923A1 (en) Compositions and methods for treating disease
CN102369012B (zh) 氧化氘用于治疗病毒性呼吸道疾病的用途
US20250032486A1 (en) Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections
WO2023144614A1 (en) Nasal compositions and methods thereof
US20240252431A1 (en) Pulmonary biguanide formulations and delivery devices
HK40114977A (zh) 用於治疗冠状病毒感染的5-氨基-2，3-二氢-1，4-酞嗪二酮与6’-甲氧基辛可宁-9-醇的组合
WO2025174376A1 (en) Compositions and methods for bimodal anti-viral combination therapy
TW201717936A (zh) 噴霧器用組成物
WO2013005020A1 (en) Method of producing a nebuliser composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240405

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250821

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251111